Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Systole

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43873   clinical trials with a EudraCT protocol, of which   7292   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    11 result(s) found for: Systole. Displaying page 1 of 1.
    EudraCT Number: 2006-000978-68 Sponsor Protocol Number: Start Date*: 2006-12-18
    Sponsor Name:AstraZeneca
    Full Title: Treatment of systemic effects in patients with COPD
    Medical condition: Chronic obstructive pulmonary disease (COPD) is a preventable and treatable disease state characterized by airflow limitation that is not fully reverible. The airflow limitation is usually progress...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-004512-11 Sponsor Protocol Number: FJD-VITDAMI-14-01 Start Date*: 2015-08-06
    Sponsor Name:INSTITUTO DE INVESTIGACION SANITARIA FJD
    Full Title: Multicenter, randomized, double-blind, placebo-controlled study to evaluate the effect of vitamin D on ventricular remodeling in patients with acute myocardial infarction: Test VITDAMI (Vitamin D i...
    Medical condition: Acute myocardial infarction with ST segment elevation anterior
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001476-63 Sponsor Protocol Number: 2014-001476-63 Start Date*: 2023-05-05
    Sponsor Name:CELLPROTHERA S.A.S
    Full Title: A multicentric controlled phase I / IIb study evaluating the safety and the efficacy of in vitro expanded peripheral blood CD34+ stem cells output by the StemXpand® Automated Process, and injected ...
    Medical condition: Severe acute myocardial Infarction. Indication : Injection of in vitro expanded peripheral blood CD34+ stem cells output by the StempXpand Automated Process, in patients with an acute myocardial in...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-000285-35 Sponsor Protocol Number: Cardoz-003 Start Date*: 2011-05-09
    Sponsor Name:Cardoz AB
    Full Title: An international, multi-centre, randomised, stratified, double-blinded, placebo-controlled, 4-parallel group trial investigating the efficacy and safety of three different dose levels of CRD007 a...
    Medical condition: Abdominal aortic aneurysm (AAA) is a dilatation of the aorta as it passes through the abdomen, defined as a dilatation of the infra-renal aorta to a diameter of 30 mm. AAA is generally asymptom...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10047065 - Vascular disorders 10000054 Abdominal aortic aneurysm LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2017-004521-32 Sponsor Protocol Number: D5780C00007 Start Date*: 2018-08-22
    Sponsor Name:MedImmune LLC, a wholly owned subsidiary of AstraZeneca PLC
    Full Title: A Randomized, Placebo-controlled Phase 2b Study to Evaluate the Safety and Efficacy of MEDI6012 in Acute ST Elevation Myocardial Infarction
    Medical condition: ST-elevation myocardial infarction
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10064345 ST segment elevation myocardial infarction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) NL (Completed) CZ (Completed) SK (Completed) HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-005405-78 Sponsor Protocol Number: 2011430 Start Date*: 2012-02-01
    Sponsor Name:Steen Bendix Haugaard
    Full Title: Adding liraglutide to the backbone therapy of biguanide in patients with coronary artery disease and newly diagnosed type-2 diabetes
    Medical condition: Patients suffering of both Type 2 diabetes mellitus and coronary artery disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10011079 Coronary artery disease NOS LLT
    14.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-005093-19 Sponsor Protocol Number: AT251-G-17-005 Start Date*: 2019-01-08
    Sponsor Name:Akros Pharma Inc.
    Full Title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JTT-251 Administered for 24 Weeks to Participants with Heart Failure with Reduced E...
    Medical condition: Heart Failure with Reduced Ejection Fraction (HFrEF)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10078289 Heart failure with reduced ejection fraction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) HU (Completed) DK (Prematurely Ended) NL (Completed)
    Trial results: View results
    EudraCT Number: 2018-002824-17 Sponsor Protocol Number: ACCOST-HH Start Date*: 2019-02-28
    Sponsor Name:University Medical Centre Hamburg-Eppendorf
    Full Title: Placebo-controlled, double-blind, randomized trial to assess the efficacy and safety of Adrecizumab in subjects with cardiogenic shock
    Medical condition: Cardiogenic shock
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007625 Cardiogenic shock PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-002931-95 Sponsor Protocol Number: LCC2010.01 Start Date*: 2008-01-30
    Sponsor Name:UZ Leuven
    Full Title: The Effects of Nitric Oxide for Inhalation on Myocardial Infarction Size.
    Medical condition: Myocardial Infarction
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10028596 Myocardial infarction PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Prematurely Ended) HU (Completed)
    Trial results: View results
    EudraCT Number: 2013-002312-27 Sponsor Protocol Number: 13-031 Start Date*: 2013-08-14
    Sponsor Name:Zealand Pharma
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Assess Clinical Efficacy and Safety of Danegaptide in Patients with ST-Elevation Myocardial Infarction undergoing Primary Per...
    Medical condition: The treatment of acute myocardial infarction, AMI is aimed at enabling the return of blood flow to the ischemic myocardium, thereby limiting the size of the infarct. However the reperfusion by itse...
    Disease: Version SOC Term Classification Code Term Level
    16.1 10047065 - Vascular disorders 10063837 Reperfusion injury PT
    16.1 100000004849 10064345 ST segment elevation myocardial infarction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2008-006755-44 Sponsor Protocol Number: 2008-510 Start Date*: 2009-01-15
    Sponsor Name:HOSPICES CIVILS DE LYON
    Full Title: METAFORE : Maladie de Rendu-Osler : Etude de l’Efficacité et de la tolérance du Bevacizumab utilisé pour le traitement des formes hépatiques sévères. Etude de phase II
    Medical condition: Maladie de Rendu-Osler
    Disease: Version SOC Term Classification Code Term Level
    9.1 10031132 Osler-Weber-Rendu disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 06 21:27:02 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA